Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BDC-4182 Phase 1 dose-escalation study now open for enrollmentBDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy anti-tumor activity Bolt is running a partnering process to advance development of BDC-3042Cash balance of $58.0 million as of March 31, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical ...